BP

:   biological process

CC

:   cellular component

DAVID

:   Database for Annotation, Visualization, and Integrated Discovery

FN

:   false negative

FP

:   false positive

GEO

:   Gene Expression Omnibus

GEPIA

:   Gene Expression Profiling Interactive Analysis

GO

:   gene ontology

HNSCC

:   head and neck squamous cell carcinoma

IGF1R

:   insulin‐like growth factor 1 receptor

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

LR

:   likelihood ratio

MF

:   molecular function

MTOR

:   mechanistic target of rapamycin

PDGFRB

:   platelet‐derived growth factor receptor, beta polypeptide

PIK3CD

:   phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit data

PPI

:   protein--protein interaction

ROC

:   receiver operating characteristic

SCC

:   squamous cell carcinoma

TCGA

:   The Cancer Genome Atlas

TN

:   true negative

TNM

:   tumor, node, and metastasis

TP

:   true positive

Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, are cancers that derived from squamous epithelial cells, which occur in the head and neck, thyroid, esophagus, lung, penis, prostate, bladder, vagina, and cervix [1](#feb412478-bib-0001){ref-type="ref"}, [2](#feb412478-bib-0002){ref-type="ref"}, [3](#feb412478-bib-0003){ref-type="ref"}, [4](#feb412478-bib-0004){ref-type="ref"}, [5](#feb412478-bib-0005){ref-type="ref"}, [6](#feb412478-bib-0006){ref-type="ref"}, [7](#feb412478-bib-0007){ref-type="ref"}, [8](#feb412478-bib-0008){ref-type="ref"}, [9](#feb412478-bib-0009){ref-type="ref"}. Of these, head and neck SCC (HNSCC) has attracted the attention of researchers due to its significant etiology including tobacco [10](#feb412478-bib-0010){ref-type="ref"}, alcohol [11](#feb412478-bib-0011){ref-type="ref"}, and human papilloma virus infection [12](#feb412478-bib-0012){ref-type="ref"} associated with people\'s lifestyles. HNSCCs, the most frequent head and neck neoplasms, are originating from squamous cells in the nasal and oral cavity, paranasal sinuses, pharynx, larynx, and salivary glands. Men are at a higher risk of HNSCC than women. In particular, cancers of the oral cavity and pharynx were reported to cause 49 670 new cases and 9700 deaths worldwide in 2017 and were the ninth highest cause of new cancer cases in men.

A deeper understanding of HNSCC is accompanied with some remarkable explorations for diagnosis, prognosis, and potential pathogenesis [1](#feb412478-bib-0001){ref-type="ref"}, [13](#feb412478-bib-0013){ref-type="ref"}, [14](#feb412478-bib-0014){ref-type="ref"}, [15](#feb412478-bib-0015){ref-type="ref"}, [16](#feb412478-bib-0016){ref-type="ref"}, [17](#feb412478-bib-0017){ref-type="ref"}. Current treatment trends include targeted therapy combined with essential chemotherapy, radiotherapy, or immunotherapy [18](#feb412478-bib-0018){ref-type="ref"}, [19](#feb412478-bib-0019){ref-type="ref"}, [20](#feb412478-bib-0020){ref-type="ref"}, [21](#feb412478-bib-0021){ref-type="ref"}, [22](#feb412478-bib-0022){ref-type="ref"}, [23](#feb412478-bib-0023){ref-type="ref"}. Despite this progress, the increasing morbidity, mortality, and complex pathological changes of HNSCC urgently necessitate more effective means for its diagnosis and treatment, especially targeted treatments based on the further exploration of novel biomarkers.

MicroRNAs (miRNAs) are small noncoding RNAs with 21--25 nucleotides, which have been confirmed to be involved in the initiation and development of multiple SCCs [24](#feb412478-bib-0024){ref-type="ref"}, [25](#feb412478-bib-0025){ref-type="ref"}, [26](#feb412478-bib-0026){ref-type="ref"}, [27](#feb412478-bib-0027){ref-type="ref"}, [28](#feb412478-bib-0028){ref-type="ref"}, [29](#feb412478-bib-0029){ref-type="ref"}. Studies have shown significantly aberrant expression of several miRNAs in HNSCCs [27](#feb412478-bib-0027){ref-type="ref"}, [30](#feb412478-bib-0030){ref-type="ref"}, [31](#feb412478-bib-0031){ref-type="ref"}, [32](#feb412478-bib-0032){ref-type="ref"}, [33](#feb412478-bib-0033){ref-type="ref"}, indicating that miRNA expression levels may be valuable for the clinical diagnosis and prognosis of HNSCC. There is a strong need to characterize the clinical application of miRNAs for HNSCC. Among validated miRNAs, miR‐99a‐5p, the major member of miR‐99a family, has been demonstrated to be associated with carcinogenesis and deterioration in several cancers such as breast cancer, endometrial carcinoma, osteosarcoma, bladder cancer, lung adenocarcinoma, and hepatocellular carcinoma [34](#feb412478-bib-0034){ref-type="ref"}, [35](#feb412478-bib-0035){ref-type="ref"}, [36](#feb412478-bib-0036){ref-type="ref"}, [37](#feb412478-bib-0037){ref-type="ref"}, [38](#feb412478-bib-0038){ref-type="ref"}, [39](#feb412478-bib-0039){ref-type="ref"}. Several genes have been found to be regulated by miR‐99a‐5p, which is also enriched in relevant biological pathways [35](#feb412478-bib-0035){ref-type="ref"}, [40](#feb412478-bib-0040){ref-type="ref"}, [41](#feb412478-bib-0041){ref-type="ref"}, [42](#feb412478-bib-0042){ref-type="ref"}, [43](#feb412478-bib-0043){ref-type="ref"}, [44](#feb412478-bib-0044){ref-type="ref"}, [45](#feb412478-bib-0045){ref-type="ref"}.

In HNSCCs, miR‐99a‐5p has been reported to be downregulated in cancerous tissues [46](#feb412478-bib-0046){ref-type="ref"}, [47](#feb412478-bib-0047){ref-type="ref"}. Nevertheless, its functional role and relevant mechanism remain to be fully elucidated. In this study, based on the data acquired from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and relevant literature, and using prediction tools (Fig. [1](#feb412478-fig-0001){ref-type="fig"}), we calculated the expression level and clinical value of miR‐99a‐5p, and performed biological analysis. This study might provide a comprehensive explanation of the clinical value and underlying mechanism of miR‐99a‐5p in HNSCC, to identify abnormally expressed miRNAs involved in HNSCC.

![Flowchart of the study design.](FEB4-8-1280-g001){#feb412478-fig-0001}

Materials and methods {#feb412478-sec-0002}
=====================

TCGA data in HNSCC patients {#feb412478-sec-0003}
---------------------------

Mature expression data of miR‐99a‐5p in HNSCC and clinical information were obtained from TCGA datasets via UCSC (<http://xena.ucsc.edu/>; Accession Number: MIMAT0000097). The IIIuminaHiseq platform included 483 HNSCC patients and 44 adjacent noncancerous head and neck tissues, while the IIIuminaGA platform included 36 patients with HNSCC. No further transformation was performed for the expression data. We explored the possible association between miR‐99a‐5p expression and clinical parameters for HNSCC patients using the two platforms together or the IIIuminaHiseq platform alone, for further comparison of these two approaches. Based on TCGA data, the diagnostic and prognostic significance of miR‐99a‐5p was evaluated using the receiver operating characteristic (ROC) curve and the Kaplan--Meier curve, respectively.

Microarray data acquisition and extraction {#feb412478-sec-0004}
------------------------------------------

We obtained available miRNA expression profiling of HNSCC from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) and ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>). The search terms were as follows: ('head AND neck' OR 'laryngeal' OR 'salivary gland' OR 'lip' OR 'mouth' OR 'tongue' OR 'nasopharyngeal' OR 'pharyngeal' OR 'OSCC' OR 'oral squamous cell' OR 'laryngeal' OR 'HNSCC') AND ('carcinoma' OR 'tumor' OR 'cancer' OR 'neoplas\*' OR 'malignan\*'). Microarray datasets were eligible with the entry criteria listed below: (1) Patients in each dataset were diagnosed with HNSCC; (2) both cancerous and noncancerous specimens were included in each dataset with a sample size of no less than three per group; and (3) miR‐99a‐5p expression data should be provided. Several relevant elements were extracted from the microarray datasets: author, publication year, country, platform, sample size, and miR‐99a‐5p expression level. Two authors (Yu‐ting Chen and Jianni Yao) independently extracted essential information from all selected chips. Conflicting opinions were solved by a discussion.

In addition, we searched the PubMed, Web of Science, Cochrane, Wiley Online Library, Ovid, EMBASE, CNKI, and VIP databases for relevant articles. The following strategy was constructed for searching: (microRNA‐99 OR hsa‐mir‐99 OR miR‐99 OR MIRN99a microRNA OR microRNA‐99a OR miR‐99a OR hsa‐mir‐99a OR MIRN99A OR mir‐99a) AND ('head AND neck' OR 'laryngeal' OR 'salivary gland' OR 'lip' OR 'mouth' OR 'tongue' OR 'nasopharyngeal' OR 'pharyngeal' OR 'OSCC' OR 'oral squamous cell' OR 'laryngeal' OR 'HNSCC') AND ('carcinoma' OR 'tumor' OR 'cancer' OR 'neoplas\*' OR 'malignan\*'). Studies that provided case numbers, mean, and standard deviation (SD) were included.

Statistical analysis {#feb412478-sec-0005}
--------------------

Statistical analyses were performed using SPSS 23.0 (IBM, NY, USA) and Stata version 12.0. Scatter diagrams were plotted for each study using GraphPad Prism 7.0. We also used SPSS 23.0 to calculate the mean ± SD for all the studies based on the expression value of miR‐99a‐5p. Stata version 12.0 was used to perform continuous variable meta‐analysis by evaluating the overall SMD and 95% CI. Both fixed‐effect and random‐effect model were employed, while the heterogeneity was analyzed by chi‐square and *I* ^*2*^ tests. Sensitivity analysis was added to explain the heterogeneity. Results were considered statistically significant if the observed SMD with 95%CI did not cross 0. Additionally, we constructed Begg\'s funnel and Egger\'s plot to detect publication bias.

For diagnostic tests, we used SPSS 23.0 to plot the ROC curve and to calculate the true positive (TP), false positive (FP), false negative (FN), and true negative (TN) for each included study. Then, diagnosis meta‐analysis was performed via MetaDisc 1.4. Sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (−LR), and diagnostic odds ratio (OR), as well as the summarized ROC curve (SROC), were chosen to describe the possible diagnostic value of miR‐99a‐5p for HNSCC. For practical application, we made a conclusion via the overall consideration of our diagnosis test results and the provided body fluid samples.

Bioinformatics analyses {#feb412478-sec-0006}
-----------------------

To predict the putative target genes of miR‐99a‐5p, we acquired candidate genes from <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85614> (log2FC \< 0), TCGA database (log2FC \> 1 and *P* \< 0.05). The miRwalk 2.0, which included miRWalk, Targetscan, miRanda, miRDB, miRNAMap, miRBridge, RNA22, miRMap, PITA, RNAhybrid, PicTar, and Microt4, was also applied to selected genes with a computer algorithm. Genes overlapping at least two prediction platforms were selected. Based on the above source, prospective genes were screened through intersection by online tools (<http://bioinformatics.psb.ugent.be/webtools/Venn/>). Meanwhile, validated genes from publications were also added.

Based on the predicted target genes, we conducted Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis using online tools (<https://david.ncifcrf.gov/>) to determine the underlying mechanism of miR‐99a‐5p in HNSCC. The STRING database (<https://string-db.org/>) was also utilized to construct a PPI network for further characterizing the interactions among promising target genes of miR‐99a‐5p. Furthermore, hub genes with over five degrees were selected. In addition, we acquired differentially expressed genes of HNSCC from the Gene Expression Profiling Interactive Analysis (GEPIA) (\|log2FC\| \> 1.5, *P* \< 0.05) and conducted another KEGG pathway analysis to detect the potential pathways for the progression of HNSCC.

Expression of hub genes and their correlations with miR‐99a‐5p {#feb412478-sec-0007}
--------------------------------------------------------------

Based on GEPIA [48](#feb412478-bib-0048){ref-type="ref"}, we detected the expression of hub genes in HNSCC and normal tissues to further identify the target genes of miR‐99a‐5p. We also performed Spearman\'s correlation analysis to explain the correlation between hub genes and miR‐99a‐5p. Besides, the protein level of those hub genes was acquired from The Human Protein Atlas.

Results {#feb412478-sec-0008}
=======

Relationships between miR‐99a‐5p expression and clinicopathological parameters in HNSCC {#feb412478-sec-0009}
---------------------------------------------------------------------------------------

Statistical analysis based on the IIIuminaHiseq platform (Table [1](#feb412478-tbl-0001){ref-type="table"}) revealed that miR‐99a‐5p was expressed at a lower level in HNSCC tissues than in normal tissues (7.987 ± 1.467 vs 10.348 ± 0.625, respectively; *P* \< 0.001). In addition, miR‐99a‐5p was expressed at higher levels in G1--G2 than in G3--G4 neoplasms (8.140 ± 1.239 vs 7.968 ± 1.525, respectively, *P* = 0.001). When statistical analysis was carried out using a combination of the IIIuminaHiseq and IIIuminaGA platforms (Table [2](#feb412478-tbl-0002){ref-type="table"}), the results revealed that miR‐99a‐5p was expressed at lower levels in HNSCC tissues than in adjacent normal tissues (8.028 ± 1.498 vs 10.348 ± 0.625, respectively, *P* \< 0.001). Significant differences were also observed among neoplasms of different histological grades (7.841 ± 1.410 vs 8.413 ± 1.622, respectively, *P* \< 0.001). In addition, miR‐99a‐5p expression was higher in patients over 50 years than in those less than 50 years (8.090 ± 1.453 vs 7.691 ± 1.695, respectively, *P* = 0.027). As for the diagnostic test based on TCGA, miR‐99a‐5p might show significant diagnostic value for HNSCC (AUC = 0.934, *P* \< 0.001; AUC = 0.926, *P* \< 0.001; Fig. [2](#feb412478-fig-0002){ref-type="fig"}). However, the tissue types of patients were unknown. Additionally, survival analysis indicated a probable prognostic value for HNSCC patients (*P* \< 0.01; Fig. [3](#feb412478-fig-0003){ref-type="fig"}). The added IIIuminaGA platform did not significantly affect our research; nevertheless, it reminds us of the need for more samples for further exploration of the relationships between miR‐99a‐5p expression and clinicopathological parameters of HNSCC patients.

###### 

Relationships between the expression value of miR‐99a‐5p and clinicopathological parameters in HNSCC patients based on the IIIuminaHiseq platform

  Clinicopathological features   *n*            miR‐99a‐5p expression level   *P* value        
  ------------------------------ -------------- ----------------------------- ---------------- ----------
  Tissue                         Noncancerous   44                            10.348 ± 0.625   \< 0.001
  Cancerous                      483            7.987 ± 1.467                                  
  Gender                         Male           351                           8.046 ± 1.515    0.152
  Female                         132            7.831 ± 1.323                                  
  Age                            ≥ 50           405                           8.040 ± 1.424    0.061
  \< 50                          77             7.698 ± 1.660                                  
  T                              T1--T2         172                           8.092 ± 1.477    0.05
  T3--T4                         251            7.817 ± 1.371                                  
  N                              N0             163                           8.005 ± 1.374    0.308
  N1--N3                         227            7.854 ± 1.482                                  
  M                              M0             174                           8.008 ± 1.482    0.139
  M1                             1                                                             
  Stage                          I--II          109                           8.140 ± 1.239    0.282
  III--IV                        361            7.968 ± 1.525                                  
  Histologic grade               G1--G2         341                           7.816 ± 1.393    0.001
  G3--G4                         122            8.332 ± 1.582                                  
  Lymphovascular invasion        Yes            113                           7.968 ± 1.458    0.180
  No                             211            7.747 ± 1.388                                  
  Alcohol                        Yes            319                           8.046 ± 1.445    0.194
  No                             156            7.859 ± 1.521                                  

John Wiley & Sons, Ltd

###### 

Relationships between the expression value of miR‐99a‐5p and clinicopathological parameters in HNSCC patients based on the IIIuminaHiseq and IIIuminaGA platforms

  Clinicopathological features   *n*            miR‐99a‐5p expression level   *P* value        
  ------------------------------ -------------- ----------------------------- ---------------- -------
  Tissue                         Noncancerous   44                            10.348 ± 0.625   0.001
  Cancerous                      519            8.028 ± 1.498                                  
  Gender                         Male           379                           8.079 ± 1.558    0.198
  Female                         140            7.889 ± 1.317                                  
  Age                            ≥ 50           436                           8.090 ± 1.453    0.027
  \< 50                          82             7.691 ± 1.695                                  
  T                              T1 \~ T2       184                           8.097 ± 1.475    0.117
  T3 \~ T4                       272            7.882 ± 1.402                                  
  N                              N0             175                           8.034 ± 1.386    0.314
  N1 \~ N3                       245            7.890 ± 1.486                                  
  M                              M0             187                           8.076 ± 1.488    0.153
  M1                             1                                                             
  Stage                          I--II          115                           8.174 ± 1.267    0.300
  III--IV                        390            8.010 ± 1.559                                  
  Histologic grade               G1--G2         368                           7.841 ± 1.410    0.001
  G3--G4                         130            8.413 ± 1.622                                  
  Lymphovascular invasion        Yes            122                           7.988 ± 1.451    0.282
  No                             229            7.814 ± 1.424                                  
  Alcohol                        Yes            346                           8.065 ± 1.474    0.366
  No                             164            7.936 ± 1.563                                  

John Wiley & Sons, Ltd

![Receiver operating characteristic (ROC) curves of miR‐99a‐5p in HNSCC based on TCGA data. (A) Diagnostic value of miR‐99a‐5p for HNSCC based on the IIIuminaHiseq platform (AUC = 0.934, *P* \< 0.001). (B) Diagnostic value of miR‐99a‐5p for HNSCC based on the IIIuminaHiseq and IIIuminaGA platforms (AUC = 0.926, *P* \< 0.001).](FEB4-8-1280-g002){#feb412478-fig-0002}

![Kaplan--Meier curves of different miR‐99a‐5p expression levels based on TCGA data. (A) The overall survival of HNSCC patients varies with different miR‐99a‐5p expression levels based on the IIIuminaHiseq platform (*P* \< 0.01). (B) The overall survival of HNSCC patients varies with different miR‐99a‐5p expression levels based on the IIIuminaHiseq and IIIuminaGA platforms (*P* \< 0.01).](FEB4-8-1280-g003){#feb412478-fig-0003}

Comprehensive meta‐analysis based on microarrays {#feb412478-sec-0010}
------------------------------------------------

### MiR‐99a‐5p expression level in HNSCC {#feb412478-sec-0011}

A total of 18 eligible microarrays were selected from GEO datasets. Finally, 924 HNSCC tissues and 212 noncancerous head and neck tissues were included as <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34496> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73460> acted equally. However, no publications met our criteria. Then, continuous variable meta‐analysis pooled the expression data from 17 microarrays (Table [3](#feb412478-tbl-0003){ref-type="table"}), among which there were 6 significant microarrays (*P* ≤ 0.05; Fig. [4](#feb412478-fig-0004){ref-type="fig"}). Other microarrays without statistical significance were displayed in Fig. [S1](#feb412478-sup-0001){ref-type="supplementary-material"} (A‐K). As the overall result revealed, miR‐99a‐5p expression was lower in HNSCC tissue than in the control group both for fixed‐effect (SMD = −0.60, 95% CI = −0.78 to −0.42, *I* ^*2*^ = 87.5%) and random‐effect (SMD = −0.54, 95% CI = −1.06 to −0.01, *I* ^*2*^ = 87.5%) models (Fig. [5](#feb412478-fig-0005){ref-type="fig"}). Sensitivity analysis was then carried out to evaluate the influence of each chip. <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45238> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32960> might be the sources of heterogeneity (Fig. [6](#feb412478-fig-0006){ref-type="fig"}). Additionally, Begg\'s funnel and Egger\'s plot indicated no obvious publication bias (Fig. [7](#feb412478-fig-0007){ref-type="fig"}).

###### 

Basic characteristics and data of the included microarrays

  Accession                                                      Author                  Year   Country       Platform   Sample   Exp mean ± Exp SD    Ctrl mean ± Ctrl SD   TP    FP   FN    TN
  -------------------------------------------------------------- ----------------------- ------ ------------- ---------- -------- -------------------- --------------------- ----- ---- ----- ----
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE11163>   Avissar M *et al*.      2008   USA           GPL6680    21       8.952 ± 1.693        10.531 ± 0.792        12    1    4     4
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE22587>   Li T *et al*.           2013   China         GPL8933    12       560.969 ± 304.226    540.273 ± 73.556      3     0    5     4
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28100>   Jung HM *et al*.        2012   USA           GPL10850   20       8.151 ± 1.449        8.167 ± 1.431         15    2    2     1
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31277>   Severino P *et al*.     2014   Brazil        GPL4133    30       13.218 ± 0.97        14.45 ± 0.418         15    2    0     13
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32906>   Luo Z *et al*.          2012   China         GPL11350   22       6780.977 ± 3169.49   3233.222 ± 1786.07    16    6    0     0
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32960>   Ma J *et al*.           2012   China         GPL14722   330      9.913 ± 0.808        11.433 ± 0.888        242   3    70    15
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34496>   Ochs MF *et al*.        2013   USA           GPL8786    69       7.215 ± 1.202        7.762 ± 0.858         27    8    17    17
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36682>   Wei R *et al*.          2012   China         GPL15311   68       12.56 ± 1.001        13.513 ± 0.391        40    0    22    6
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41268>   Xie Z *et al*.          2012   China         GPL10850   10       5.978 ± 0.995        5.499 ± 0.703         1     0    6     3
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43039>   Li X *et al*.           2015   China         GPL16414   40       −0.053 ± 3.322       −0.515 ± 1.23         2     0    18    20
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43329>   Zheng X *et al*.        2013   China         GPL16475   50       102.21 ± 30.963      98.606 ± 0.583        6     2    25    17
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45238>   Shiah S *et al*.        2015   Taiwan        GPL8179    80       4094.715 ± 2167.8    9774.709 ± 1957.02    38    4    2     36
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46172>   Plieskatt JL *et al*.   2014   USA           GPL16770   8        8.262 ± 2.384        9.443 ± 0.614         2     0    2     4
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE62819>   Lian M *et al*.         2014   China         GPL16384   10       10.288 ± 1.185       11.078 ± 1.012        4     1    1     4
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69002>   Creighton C *et al*.    2016   USA           GPL18044   7        3.305 ± 0.058        3.405 ± 0.115         3     2    0     2
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70970>   Bruce J *et al*.        2015   Canada        GPL20699   263      9.078 ± 2.033        9.421 ± 0.891         73    1    173   16
  <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82064>   Valeri N *et al*.       2017   Switzerland   GPL21968   96       212.885 ± 194.605    139.667 ± 60.085      21    4    57    14

John Wiley & Sons, Ltd

![Representative scatter plots of miR‐99a‐5p expression data in normal and HNSCC tissues in microarrays. Expression data of miR‐99a‐5p in normal and HNSCC tissues from microarrays with *P* value ≤ 0.05 were plotted: (A) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31277> (*P* \< 0.001). (B) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32906> (*P* = 0.018). (C) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32960> (*P* \< 0.001). (D) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34496> (*P* = 0.050). (E) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36682> (*P* = 0.024). (F) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45238> (*P* \< 0.001).](FEB4-8-1280-g004){#feb412478-fig-0004}

![MiR‐99a‐5p expression levels in normal tissue and HNSCC by forest plot. (A) Forest plot constructed by the fixed‐effect model (SMD = −0.60, 95% CI= −0.78 to −0.42, *I* ^*2*^ = 87.5%). (B) Forest plot constructed by the random‐effect model (SMD = −0.54, 95% CI = −1.06 to −0.01, *I* ^*2*^ = 87.5%).](FEB4-8-1280-g005){#feb412478-fig-0005}

![Sensitivity analysis. (A) Fixed‐effect model. (B) Random‐effect model. <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45238> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32960> might be sources of heterogeneity according to the fixed‐effect model.](FEB4-8-1280-g006){#feb412478-fig-0006}

![Publication bias detection. (A) Begg\'s funnel. (B) Egger\'s plot.](FEB4-8-1280-g007){#feb412478-fig-0007}

### Diagnostic value of miR‐99a‐5p for HNSCC {#feb412478-sec-0012}

ROC curves for all eligible studies were plotted. Four representative ROC curves including <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31277>, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32960>, <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36682> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45238> were displayed in Fig. [8](#feb412478-fig-0008){ref-type="fig"}, with *P* value less than 0.05, while the other studies showing no statistical significance were in Fig. [S1](#feb412478-sup-0001){ref-type="supplementary-material"} (L‐X). Further analysis was performed based on the TP, FP, FN, and TN results (Table [3](#feb412478-tbl-0003){ref-type="table"}). As shown in Fig. [9](#feb412478-fig-0009){ref-type="fig"}, the SROC curve verified the diagnostic value of miR‐99a‐5p in HNSCC as the AUC was 0.85 (95% CI = 0.77--0.92), with a sensitivity of 0.56 (95%CI=0.52--0.59, *P* \< 0.001) and a specificity of 0.85 (95% CI = 0.80--0.90, *P* = 0.030). Furthermore, likelihood ratios were calculated (Pool +LR = 2.90, 95% CI = 1.91--4.39, *P* = 0.074; pool −LR = 0.52, 95% CI = 0.38--0.73, *P* \< 0.001), respectively. The diagnostic OR of 8.23 (95% CI = 3.71--18.25, *P* = 0.006) also suggested a significant diagnostic value when based on all the included samples. However, only the <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41268> and <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69002> chips provided body fluid samples (AUC = 0.333, *P* = 0.201 and AUC = 0.750, *P* = 0.197, respectively). Thus, the clinical diagnostic value of miR‐99a‐5p for HNSCC could not be fully verified.

![Representative ROC curves of the microarrays. ROC curve of miR‐99a‐5p expression in normal and HNSCC tissues from microarrays with *P* value ≤ 0.05 were plotted: (A) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31277> (AUC = 0.947, *P* = 0.046). (B) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32960> (AUC = 0.890, *P* = 0.033). (C) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45238> (AUC = 0.967, *P* = 0.018). (D) <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70970> (AUC = 0.539, *P* = 0.050).](FEB4-8-1280-g008){#feb412478-fig-0008}

![Diagnostic test based on the 17 included microarrays. (A) The summarized receiver operating characteristic (SROC) curve (AUC = 0.85, 95% CI = 0.77--0.92 calculated manually). (B) Sensitivity value of 0.56 (95%CI = 0.52--0.59, *P* \< 0.001). (C) Specificity value of 0.85 (95% CI = 0.80--0.90, *P* = 0.030). (D) Pool positive likelihood ratio of 2.90 (95% CI = 1.91--4.39, *P* = 0.074). (E) Pool negative likelihood ratio of 0.52 (95% CI = 0.38--0.73, *P* \< 0.001). (F) Diagnostic odds ratio of 8.23 (95% CI = 3.71--18.25, *P* = 0.006).](FEB4-8-1280-g009){#feb412478-fig-0009}

Bioinformatics analyses of miR‐99a‐5p and HNSCC {#feb412478-sec-0013}
-----------------------------------------------

### Prediction of miR‐99a‐5p target genes {#feb412478-sec-0014}

We screened 14 174 genes from GSM2279805, 1532 genes from the TCGA dataset, and 3085 genes from miRwalk 2.0 after removing duplicates. As the analytical integration shown, a total of 98 genes overlapped in the GSM microarray and online software (Fig. [10](#feb412478-fig-0010){ref-type="fig"}). *MTMR3*,*IGF1R*,*MTOR*,*NOX4,* and *HOXA1*, which were searched from published literature, were also included [49](#feb412478-bib-0049){ref-type="ref"}, [50](#feb412478-bib-0050){ref-type="ref"}, [51](#feb412478-bib-0051){ref-type="ref"}, [52](#feb412478-bib-0052){ref-type="ref"}, [53](#feb412478-bib-0053){ref-type="ref"}. Finally, a total of 103 genes were identified as the promising target genes of miR‐99a‐5p in HNSCC (Table [4](#feb412478-tbl-0004){ref-type="table"}).

![Venn diagram for identifying 98 promising target genes of miR‐99a‐5p in HNSCC.](FEB4-8-1280-g010){#feb412478-fig-0010}

###### 

Validated genes of miR‐99a‐5p from the GEO, TCGA, and miRwalk databases and literature

                                        Genes                                                 
  ------------------------------------- ---------- ---------- -------- ---------- ----------- ------
  Validated in HNSCC                    MTMR3      IGF1R      MTOR     NOX4       HOXA1       
  Validated by analytical integration   LAMA5      AGO2       HIP1     SLC44A1    TNFAIP8L1   POLE
  RELB                                  U2SURP     RNF213     DNASE2   MPP3       TRAM2       
  LHFPL2                                NCS1       FAM64A     TTYH3    HSP90B1    GUCY1A3     
  WNT7B                                 CELSR1     SLC39A14   MXRA8    NRIP3      PAPLN       
  ASNS                                  PIK3CD     NAV1       FANCA    STK10      AFAP1L1     
  B4GALNT1                              TAPBP      WARS       TUSC3    CASK       PRSS23      
  HENMT1                                ACVR1      ANGPT2     BICD1    DLX5       RGS3        
  ABCG1                                 ITGA3      SH2B3      COL5A1   CTLA4      ECE1        
  ETS1                                  EXT2       FOXM1      BCAM     MN1        PDGFRB      
  PYCR1                                 MAPK12     SLC1A4     GPR68    STC2       UBE2L6      
  SCRN1                                 IGF2BP2    TSPAN9     SLC2A6   KIAA0930   FLRT2       
  TMEM184B                              DKK3       EPB41L4B   KIRREL   YEATS2     IPO9        
  FAM111A                               STRA6      ORAI2      LBH      APH1B      KRBA1       
  RNASE7                                MARVELD3   C1QTNF1    ANTXR2   GJB4       C10orf35    
  NPNT                                  SH3PXD2B   ADAM8      COL6A2   HAS2       ODC1        
  TGFB3                                 FADD       DDIT4      MISP     MFAP5      SYT7        
  ARHGEF39                              NRBP2                                                 

John Wiley & Sons, Ltd

### GO enrichment and KEGG pathway analysis {#feb412478-sec-0015}

For GO enrichment analysis, the results comprised biological process (BP), cellular component (CC), and molecular function (MF). The potential target genes of miR‐99a‐5p significantly influence 15 GO terms (*P* \< 0.05), including cell migration and phosphatidylinositol‐mediated signaling in BP, and focal adhesion in CC. Additionally, KEGG pathway analysis also indicated that the PI3K‐Akt signaling pathway and pathways in cancer were the most enriched for miR‐99a‐5p in HNSCC (*P* \< 0.001, FDR \< 0.05; Fig. [11](#feb412478-fig-0011){ref-type="fig"}). According to another KEGG pathway analysis, the PI3K‐Akt signaling pathway and pathways in cancer were also confirmed to be significant in the progression of HNSCC (*P* \< 0.001; Fig. [12](#feb412478-fig-0012){ref-type="fig"}).

![Functional annotation of target genes by GO enrichment and KEGG pathway analysis (*P* value \< 0.05 for KEGG,BP, and CC).](FEB4-8-1280-g011){#feb412478-fig-0011}

![Bubble diagram of KEGG pathway for HNSCC. Significant pathways with *P* value \< 0.01 were plotted by R language.](FEB4-8-1280-g012){#feb412478-fig-0012}

PPI network construction {#feb412478-sec-0016}
------------------------

The 103 putative target genes were inputted into STRING for constructing a PPI network (Fig. [13](#feb412478-fig-0013){ref-type="fig"}). There were 103 nodes and 49 edges with an enrichment *P* value of 0.007. Thus, we further identified *PIK3CD*,*IGF1R*,*PDGFRB*, and *MTOR* as the hub genes of miR‐99a‐5p in HNSCC (all degrees \> 5).

![PPI network of 103 promising target genes of miR‐99a‐5p in HNSCC.](FEB4-8-1280-g013){#feb412478-fig-0013}

Expression value of hub genes and their correlations with miR‐99a‐5p {#feb412478-sec-0017}
--------------------------------------------------------------------

As shown in the boxplot (Fig. [14](#feb412478-fig-0014){ref-type="fig"}), *PIK3CD*,*IGF1R*,*PDGFRB*, and *MTOR* all exhibited higher expression levels in 519 HNSCC tissues compared to the 44 normal tissues. *PIK3D* and *IGFR1* expression levels were significant negatively correlated to miR‐99a‐5p in HNSCC (PIK3D: *r* = −0.318, *P* \< 0.001; IGFR1: *r* = −0.118, *P* = 0.005), while PDGFRB and MTOR were mildly negatively correlated with miR‐99a‐5p (PDGFRB: *r* = −0.036, *P* = 0.393; MTOR: *r* = −0.012, *P* = 0.774; Fig. [15](#feb412478-fig-0015){ref-type="fig"}).

![Expression analysis of four hub genes in 44 normal tissues and 519 HNSCC tissues based on GEPIA. (A) Expression value of *PIK3CD*. (B) Expression value of *IGF1R*. (C) Expression value of *PDGFRB*. (D) Expression value of *MTOR*.](FEB4-8-1280-g014){#feb412478-fig-0014}

![Spearman\'s correlation analysis. Expression value of *PIK3CD* (A), *IGF1R* (B), *PDGFRB* (C), and *MTOR* (D) and their correlations with miR‐99a‐5p.](FEB4-8-1280-g015){#feb412478-fig-0015}

Discussion {#feb412478-sec-0018}
==========

There has been a trend of targeted treatment for human cancers in recent years. Illuminated by the abnormal biological signals in cancer cells, people commit to detecting novel biomarkers for exploring the potential mechanism of tumorigenesis and progression as well as further clinical applications such as cancer diagnosis, treatment, and prognosis. Therein, the miRNAs, which appear to be involved in gene regulation, were confirmed to be tumor suppressors or promoters [54](#feb412478-bib-0054){ref-type="ref"}, [55](#feb412478-bib-0055){ref-type="ref"}.

Several studies have demonstrated that miR‐99a‐5p could affect proliferation, migration, and invasion in various cancers, including HNSCCs, via modulating gene expression [36](#feb412478-bib-0036){ref-type="ref"}, [56](#feb412478-bib-0056){ref-type="ref"}, [57](#feb412478-bib-0057){ref-type="ref"}. The reduced miR‐99a‐5p expression was confirmed to suppress the insulin‐like growth factor mammalian of rapamycin signaling (IGF‐mTOR signaling) through binding sites in their 3ʹ‐untranslated regions (UTRs) in childhood adrenocortical tumors [58](#feb412478-bib-0058){ref-type="ref"}. According to Kuo *et al*., miR‐99a‐5p could inhibited myotubularin‐related protein 3 (MTMR3) expression then suppress the metastasis of oral cancer (OC) [49](#feb412478-bib-0049){ref-type="ref"}. As for HNSCC, Chen *et al*. also reported that IGFR1 and MTOR were repressed by ectopic transfection of miR‐99‐5p [51](#feb412478-bib-0051){ref-type="ref"}. In addition, Yan *et al*. suggested that downregulation of miR‐99a‐5p contributed to oral squamous cell carcinoma (OSCC) by targeting MTOR, further indicating the relation between miR‐99a‐5p and HNSCC development [59](#feb412478-bib-0059){ref-type="ref"}. Recently, miR‐99a‐5p was found to facilitate oral tumor cells by targeting NADPH oxidase 4 (NOX4) [52](#feb412478-bib-0052){ref-type="ref"}. To achieve a deeper understanding of the mechanism underlying miR‐99a‐5p, we identified its potential targets and performed the comprehensive biological pathway analysis. According to our KEGG pathway analysis, miR‐99a‐5p significantly affected the progression of HNSCC by regulating the PI3K‐Akt signaling pathway, of which the predicted target genes, phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit data (*PIK3CD*), insulin‐like growth factor 1 receptor (*IGFR1*), platelet‐derived growth factor receptor, beta polypeptide (*PDGFRB*), and mechanistic target of rapamycin (*MTOR*) were involved.

The PI3K‐Akt signaling pathway, concretely explained as the phosphatidylinositol 3‐kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) signaling pathway, is aberrant in many types of cancer [60](#feb412478-bib-0060){ref-type="ref"}, [61](#feb412478-bib-0061){ref-type="ref"}, [62](#feb412478-bib-0062){ref-type="ref"}, [63](#feb412478-bib-0063){ref-type="ref"}. The involved *PIK3CD*,*IGFR1*,*PDGFRB*, and *MTOR4*, also screened out by PPI construction, were further utilized to analyze the correlations with miR‐99a‐5p. We found that the four hub genes all exhibited higher expression levels in HNSCC tissues than in normal tissues, gaining more possibility to be the target genes of miR‐99a‐5p. Interestingly, a negative correlation was found between these four genes and miR‐99a‐5p, with *PIK3D* and *IGFR1* showing significant negative correlation with miR‐99a‐5p in HNSCC and *PDGFRB* and *MTOR* showing a mild negative correlation. Thus, together with the findings of previous researches and our results, we speculated that the dysfunctional PI3K‐Akt signaling pathway was implicated in the development of HNSCC. Moreover, it seems that PI3K‐Akt signaling pathway was regulated by miR‐99a‐5p according to the statistical correlation analysis, which further provided evidence for the potential clinical value of miR‐99a‐5p detection in HNSCC.

Statistical analysis of miR‐99a‐5p expression would confirm our speculation. Previous studies have suggested that repressed miR‐99a‐5p may contribute to tumorigenesis via being unable to control the target genes. Thus far, no study has specifically analyzed the miR‐99a‐5p expression level in HNSCC, but several studies have demonstrated the lower expression of miR‐99a‐5p in HNSCC [46](#feb412478-bib-0046){ref-type="ref"}, [51](#feb412478-bib-0051){ref-type="ref"}, [59](#feb412478-bib-0059){ref-type="ref"}. According to our GEO meta‐analysis and TCGA data mining results, the miR‐99a‐5p expression level was markedly lower in HNSCC than in normal tissues. In addition, miR‐99a‐5p expression was higher in low neoplasm histological grades than high histological grades, and the patient\'s age may also be a possible clinical parameter. Furthermore, we found that miR‐99a‐5p showed significance in diagnostic and prognostic tests; however, due to limited body fluid samples, the results could not be used as representative and its diagnostic applicability in the clinical setting could not be determined. Thus, additional studies are needed to demonstrate the clinical role of miR‐99a‐5p in the diagnosis and prognosis of HNSCC.

This study has some limitations. First, the different miRNA extraction methods may disturb the results of our meta‐analysis. Second, the HNSCC and corresponding samples were mostly derived from tissue sections, lead to an unverified diagnostic value. Third, although we utilized TCGA data to expand our data, the big gap between the quantity of cancerous and noncancerous tissues brought down the reliability. And fourth, the resource of online protein databases and relevant immunohistochemical staining samples were limited so that we could not further validate the function of miR‐99a‐5p via the protein level of hub genes. Despite these limitations, based on our meta‐analysis, the results suggest that miR‐99a‐5p expression was significantly lower in HNSCC than in normal tissue. Biological analysis also suggested that miR‐99a‐5p may participate in HNSCC by suppressing the hub genes, *PIK3CD*,*IGFR1*,*PNGFRB,* and *MTOR*.

In general, our study confirmed that miR‐99a‐5p might be a tumor suppressor in HNSCC with downregulated expression in HNSCC tissues, via the PI3K‐Akt signaling pathway. Further studies are required to elucidate the role of miR‐99a‐5p in diagnosis and prognosis for HNSCC and provide the basis for that miR‐99a‐5p execute its function via the protein level of the targets, especially those hub genes predicted by our research.
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**Fig. S1.** (A‐K): Scatter plots of miR‐99a‐5p expression data in normal and HNSCC tissues in the other 11 microarrays without statistical significance. (L‐X): ROC curves of the other 13 microarrays without statistical significance.
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Click here for additional data file.
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